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Abstract
Background Increased bioavailability of phenylephrine is re-
ported when combined with paracetamol in over-the-counter
formulations for the symptomatic treatment of the common
cold and influenza. Such formulations could increase
phenylephrine-related cardiovascular adverse events particu-
larly in susceptible individuals. Quantification of the effect of
phenylephrine concentration on blood pressure allows simu-
lation of potential adverse combination therapy effects.
Methods MEDLINE and EMBASE databases were searched
for papers discussing or describing any adverse effect, hyper-
sensitivity or safety concerns related to phenylephrine alone or
in combination with other drugs.
The pharmacodynamic relationship between plasma phen-
ylephrine concentration and mean arterial blood pressure was
characterized using published observations of blood pressure
changes after ophthalmic eye drops. The resulting pharmaco-
kinetic and pharmacodynamic parameters were then used to
predict mean arterial blood pressure (MAP) changes in that
population if given an oral combination of phenylephrine and
paracetamol.
Results There were 1172 papers identified for examination.
Forty-seven reports fulfilled the inclusion criteria. Increases
in blood pressure and decreases in heart rate have been report-
ed with doses over 15 mg. It has been estimated that a 20-
mmHg increase in systolic blood pressure would occur with
an oral dose of 45 mg phenylephrine in normotensive healthy
people. Those taking monoamine oxidase inhibitors report
increased systolic blood pressure of greater than 60 mmHg.
Blood pressure and heart rate changes are potentiated in pa-
tients with underlying hypertension. Simulation showed a
modest increase in MAP when phenylephrine 10 mg was
co-administered with paracetamol 1 g (4.2 vs 12.3 mmHg).
Conclusions Combination paracetamol phenylephrine oral
therapy has potential to increase blood pressure more than
phenylephrine alone in those with cardiovascular
compromise.
Keywords Paracetamol . Phenylephrine . Interaction .
Pharmacodynamics . Blood pressure
Introduction
Phenylephrine is a selective alpha-1 adrenoceptor agonist with
powerful vasoconstrictive properties. Historically, its use had
been restricted to the perioperative period and intensive care
medicine for preparation of the surgical field and control of
haemorrhage during ear nose and throat procedures, pupillary
dilation and maintenance of blood pressure. Phenylephrine is
commonly used now as a nasal decongestant in many over-
the-counter (OTC) cold and influenza preparations.
When phenylephrine was combined with another com-
monly administered cold and flu medication, paracetamol,
the plasma concentration of phenylephrine was, on average,
twice that obtained when phenylephrine was given alone and
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the peak concentration approximately four times higher [1]. It
is suggested that the increase in phenylephrine bioavailability
is due to a reduction in the amount of phenylephrine under-
going first-pass metabolism due to saturation of the sulfation
pathways by paracetamol [1]. Formulation may also have im-
pact. Phenylephrine bioavailability was reduced when admin-
istered as a paracetamol-guaifenesin-phenylephrine syrup
compared to the same combination in tablet form [2]. These
findings raise the concern that phenylephrine administered as
a combination with paracetamol may increase the incidence of
adverse effects attributable to phenylephrine, most notably
cardiovascular adverse effects particularly those with
preexisting cardiovascular conditions.
Here, we provide a systematic narrative review of cardio-
vascular adverse effects associated with phenylephrine. We
quantify the effect of phenylephrine concentration on blood
pressure using published data and simulate the potential im-
pact paracetamol phenylephrine combination oral therapy
may have on cardiovascular endpoints.
Methods
Literature review of phenylephrine adverse events
Search strategy
A broad search (search terms are detailed in the
Supplementary Appendix) of both MEDLINE and EMBASE
databases was undertaken followed by manual selection of
relevant reports based on the inclusion and exclusion criteria
described below. No specific time limits were applied to the
search. The time frame of the search was limited only by the
coverage of the database (MEDLINE: 1946 to April 2014;
EMBASE: 1947 to April 2014).
Papers discussing or describing any adverse effect, hyper-
sensitivity or safety concern related to phenylephrine alone or
in combination were included. Papers were excluded if they
(1) did not describe an adverse effect for phenylephrine; (2)
related to children under 12 years of age; (3) were not written
in English or a full-text version was not available for purchase;
(4) was not a clinical trial [either prospective or retrospective],
case report or series, or a meta-analysis; and (5) did not relate
to the cardiovascular system. References of identified papers
were reviewed for additional relevant reports.
Simulation
Phenylephrine PKPD relationship analysis
The relationship between plasma phenylephrine concentration
and mean arterial blood pressure was characterized using
those published data from Kumar and colleagues [3], who
related the systemic absorption of phenylephrine eye drops
to cardiovascular effects. Individual plasma concentrations
and corresponding blood pressure changes at 0, 10, 20 and
60 min after 2.5 % (n=10) and 10 % (n=10) eye drops (two
32-μL drops at 5-min intervals) are contained in Tables 1 and
2 of that publication(n=20). Further pharmacokinetic (PK)
data were available from healthy volunteers given oral phen-
ylephrine 10 mg alone, with blood for concentration assay
taken at 5, 15, 30, and 45 min and 1, 2, 3, and 6 h (n=28, data
from [1, 4]). Intravenous time-concentration data were avail-
able from a study by Hengstmann and colleagues [5]. Four
healthy volunteers were given phenylephrine 1 mg, and blood
was taken for assay on 17 occasions over the subsequent 4 h.
Pooled data for that study are presented in Table 2 of that
publication(n=1). Technical methods for population parame-
ter estimates using nonlinear mixed effects models
(NONMEM) can be found in the Supplementary Appendix.
Results
Literature search
A total of 1172 papers were identified for examination. Forty-
seven reports fulfilled the inclusion criteria. The majority of
literature concerning phenylephrine and cardiovascular effects
related to its use as a hypertensive agent for the management
of hypotension associated with shock and spinal anaesthesia.
These effects are therapeutic in these scenarios, and as they are
not adverse effects, they are not discussed. Case reports and
studies that described unexpected or unwanted cardiovascular
effects following the use of phenylephrine are listed in
Table 1.
The standard OTC 10-mg dose of phenylephrine appears to
be well tolerated by the majority of people; however, increases
in blood pressure and decreases in heart rate are reported with
doses over 15mg [6, 7]. It has been estimated that a 20-mmHg
increase in systolic blood pressure would occur with an oral
dose of 45 mg phenylephrine in normotensive healthy people
[8]. This situation changes considerably in people taking med-
ications such as monoamine oxidase inhibitors where interac-
tion with phenylephrine caused increases in systolic blood
pressure of greater than 60 mmHg and required intervention
[9, 10]. Blood pressure and heart rate changes also appear to
be potentiated in patients with underlying hypertension. One
study reports severe hypertensive episode requiring interven-
tion in 10 % of study participants given 10 % topical drops as
a mydriatic agent in ophthalmic surgery, all of whom had
underlying hypertension; no episodes of hypertension were
reported in normotensive participants [11]. Phenylephrine
may also interact with cocaine (medical or recreational) po-
tentiating the hypertensive effects of phenylephrine [12, 13].
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Population Result Comments Reference
Oral
10—25 mg Normotensive participants
with common cold (n=48)
↑ HR cf. placebo doses ≥10 mg
↓ BP cf. placebo doses ≥15 mg
Cohen et al. [6]
10 mg Normotensive participants with
nasal congestion (n=88)
NC BP Conflicting results
—20 % of participants showed ↑ BP, while
32 % showed ↓ BP 60 min after administration
—30 % of participants showed ↑ HR, while
44 % showed ↓ HR 60 min after administration
—Nine participants had ↑HR >10 bpm
McLaurin et al.
[7]
250 mg Normotensive volunteers (n=7) Average ↓ in HR=21 bpm
Average ↑ in BP=31 mmHg
Threshold for pressor response estimated to be 50 mg. Keys and
Violante [8]
45 mg Normotensive volunteers (n=4),
concurrent MOA inhibitors
Significant ↑ in BP
Significant ↓ in HR
≥67 mmHg ↑ in BP in two participants administered
single 45-mg dose of phenylephrine after 7 days
of MOA inhibitor therapy (tranylcypromine or
phenelzine). Required intervention with
phentolamine.
Elis et al. [9]
10 mg Normotensive volunteers (n=4),
concurrent MOA inhibitors
Significant ↑ in BP 20 mmHg ↑ in BP after 10 mg phenylephrine dose
following 11 days on tranylcypromine
Elis et al. [9]
Unclear—?10 mg 74-year-old women with
comorbidities, concurrent
MOA inhibitors
Significant ↑ in BP
(hypertensive crisis—
BP up to 230/120 mmHg)
Combination of phenylephrine from an




Unclear—overdose 24-year-old otherwise healthy male Significant ↑ in BP
(196/100 mmHg, ↓ in HR
(40 bpm), third-degree
atrioventricular block
Ingestion of 30–40 tablets each containing 40 mg
phenylpropanolamine, 10 mg phenylephrine,







59-year-old otherwise healthy female ICH, SAH Took cold and flu medications containing PE,
paracetamol, dextromethorphan and
chlorpheniramine for 4 days before
hospitalization
Tark et al. [36]
Topical (eye drops, nasal packs, nasal sprays)




↑ BP following both 2.5 and
10 % eye drop in both
normotensive and hypertensive
patients.
4/30 patients in 10 % group and 1/29 patients in the
2.5 % group developed severe hypertension which
required intravenous hypotensive agents for
management—all patients who developed severe
hypertension had baseline hypertension.
Chin et al. [11]




↑ BP following both 2.5 and










Severe hypertension, unstable angina and
uncontrolled diabetes all exclusions.
Cardiovascular endpoints measured at beginning and
end of procedure—end time not defined—not
continuously monitored
Lam et al. [48]










2.5 or 10 % single
eye drop
Funduscopy (n=29) NC BP
NC HR
Normotensive participants only Motta et al. [50]




SAH, rupture cerebral aneurysm, BP 200/
108 mmHg, HR 48 bpm, death
Possible interaction with propranolol—not able to
vasodilate to counteract pressor effect of PE
Cass et al. [40]





ICH, BP 300/200 mmHg Weisberg et al.
[41]
10 % four times eye
drops
57-year-old man, no known
cardiovascular disease
Acute myocardial infarct, severe
hypertension and cardiac arrhythmia
Lai [51]
500 mg via nasal
pack








Myocardial infarct Combined with 4 % cocaine for local anaesthesia Ashchi et al.
[13]
0.25 % solution via
nasal pack
28-year-old man Acute hypertension (190/100 mmHg),
pulmonary oedema
Patient had history of smoking cocaine Singh et al. [12]
Unclear—?daily
nasal spray TID
57-year-old male ICH, SAH, occipital infarct, BP 240/
110 mmHg
Nasal spray TID for 4 months Cantu et al. [37]
Unclear—nasal
spray




45-year-old female SAH Nasal spray for many weeks Genonceaux
et al. [39]
Injectable
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Unwanted cardiovascular effects are commonly reported
when phenylephrine is administered intravenously for its hy-
pertensive effects and appear to be dose dependent [14–19].
The majority of literature relates to bradycardia and reactive
hypertension when phenylephrine was used to counter the
hypotensive effects of spinal anaesthesia during caesarean
section [14–19]. An increase in blood pressure with associated
impairment in myocardial perfusion was seen when phenyl-
ephrine was administered to patients with underlying cardiac
disease (angina pectoris, old myocardial infarct or chronic
coronary artery disease) [20]. Increased blood pressure
[21–27], vasoconstriction resulting in worsening of orthostatic
intolerance [28], atrial fibrillation after coronary artery bypass
surgery [29], decreased cerebral oxygenation [30, 31], brady-
cardia in patients with high cervical spinal cord injury [32],
cardiac arrhythmias [33], pulmonary oedema and myocardial
infarction [34], and microvascular occlusion syndrome [35]
have all been associated with phenylephrine use.
Cerebrovascular events have also been reported. Tark et al.
report the case of an otherwise healthy 50-year-old woman
who suffered intracerebral haemorrhage after oral administra-
tion of standard doses of cold medicines containing phenyl-
ephrine and paracetamol for 4 days before hospitalization









Women scheduled for elective
caesarean section (n=75)
Significant reduction (up to 20 %) in HR







Ventricular bigeminy Lai et al. [54]
150 μg iv 35-year-old woman, elective
caesarean section




↑ increase, ↓ decrease, cf. compared with, NC no change,HR heart rate, BP blood pressure, PE phenylephrine, CO cardiac output, TID three times daily,





estimates for ophthalmic PKPD
analysis
Parameter Estimate %BSV 95 % CI
Pharmacokinetics
CLstd (L h−1 70 kg−1) 139 38.3 61.5, 235.9
V1std (L 70 kg−1) 15.3 106.3 9.5, 73.9
Qstd (L h−1 70 kg−1) 30 130 23.9, 311
V2std (L 70 kg−1) 235 101 102, 562
Tabs oral (h) 0.52 40 0.34, 0.63
Lag oral (h) 0.247 – 0.21, 0.26
Bioavailability oral 0.014 0.008, 0.051








Residual error Additive (mcg L−1) 0.013 – 0.001, 0.015
Proportional (%) 32.6 25.2, 39.9
Pharmacodynamics
E0 (mmHg) 86.3 4.4 81.6, 90.2
EC50 (mcg L−1) 11.1 141 1.67. 19.9
Emax (mmHg) 51.2 44.8 20.5, 109.1
Residual error Additive (mcg L−1) 9.88 – 7.03, 11.7
Proportional (%) 61.6 – 0.6, 125
BSV between-subject parameter variability, CI confidence interval
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following phenylephrine use via topical and intravenous ad-
ministration [37–42].
PKPD relationship analysis
The pharmacokinetic/pharmacodynamic (PKPD) analysis was
based on 49 subjects (with 387 observations) who received
phenylephrine ophthalmic eye drops where plasma concentra-
tions were available for analysis. Patients had a mean age 34.3
SD 8.2 years and a mean weight 74.4 SD 3.4 kg. Pharmacoki-
netic and pharmacodynamic parameter estimates are reported
in Table 2. The correlation of between parameter variability is
shown in Table 3. PC-VPC plots, used to demonstrate goodness
of fit, are shown in Fig. 1. Figure 2 demonstrates the pharma-
codynamic relationship between phenylephrine concentration
and MAP for a typical individual.
Simulation
Pharmacodynamic parameter estimates estimated from the
phenylephrine ophthalmic study [3] were combined with de-
rived pharmacokinetic estimates from a study in healthy vol-
unteers given paracetamol and phenylephrine combination
therapy [4] to simulate mean time-concentration and mean
arterial blood pressure changes that might occur if patients
were given oral phenylephrine with and without paracetamol.
These simulations were performed using Berkeley Madon-
na™ modelling and analysis of dynamic systems software V
8.3.18 (Robert Macey and George Oster of the University of
California, Berkeley, USA).We predict an increase inMAP of
16 mmHg after 45 mg phenylephrine; i.e., a person with a BP
of 120/65 mmHg might increase to 140/80 mmHg, a systolic
increase of 20 mmHg. Plots are presented in Fig. 3. The in-
creased absorption rate of phenylephrine when combined with
paracetamol results in higher peak concentrations than might
be anticipated from increased bioavailability alone.
Discussion
Phenylephrine has now replaced pseudoephedrine in most
over-the-counter (OTC) cold and influenza medications.
There are few data reporting adverse events associated with
oral phenylephrine use. What little information available must
be gleaned from other routes of administration where more
formal studies have been conducted: phenylephrine interacts
with monoamine oxidase inhibitors and possibly other drugs
to potentiate its hypertensive effect; cardiovascular changes
may be more pronounced in people with underlying cardio-
vascular disease and may lead to decreased myocardial oxy-
genation, cardiac arrhythmias, decreased cerebral oxygenation
and exaggerated vasoconstriction and stroke.
That few adverse events following oral administration of
phenylephrine are reported is not surprising, though not nec-
essarily reflective of the actual incidence of adverse effects.
Relative oral bioavailability remains poorly documented but
may be as little as 0.003 [5]. Absorption is slow (Tabs 0.4 h,
BSV 30.8 %), and peak concentrations will be less than that
observed after rapid intravenous administration. Oral phenyl-
ephrine is generally administered in a community setting to
relieve symptoms of malaise associated with colds and influ-
enza, and as such, blood pressure changes over the short du-
ration of phenylephrine administration are unlikely to be
Table 3 The correlation of parameter between-subject variability
CL Q V1 V2 Tabs
CL 1
Q −0.799 1
V1 −0.817 0.651 1
V2 −0.630 0.093 0.533 1
Tabs 0.512 −0.463 −0.148 −0.239 1
Fig. 1 Visual predictive check for the PKPD model. All plots show
median and 90 % intervals (solid and dashed lines). Also shown are
prediction percentiles (10, 50 and 90 %) for observations (lines with
symbols) and predictions (lines) with 95 % confidence intervals for
prediction percentiles (grey-shaded areas). The upper panel is the
pharmacokinetic fit using PK data from all formulations while the
lower panel is the pharmacodynamic fit involving data only from
subjects undergoing ophthalmic surgery
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recorded. The few studies examining oral phenylephrine at the
recommended dose of 10 mg have shown it to be well toler-
ated in patients suffering from nasal congestion. However,
these studies focus on phenylephrine as a single agent and
not in combination with paracetamol where bioavailability is
increased and peak plasma concentrations doubled [1]. Fur-
thermore, these studies have primarily been conducted in ei-
ther healthy volunteers or in otherwise healthy patients with
nasal congestion.
The simulation study assumes that the administration of
phenylephrine with paracetamol more than doubles the bio-
availability of phenylephrine and reduces the absorption half-
time by 50 % resulting in a doubling of phenylephrine plasma
concentration and an approximate fourfold increase in Cmax,
with large between-subject variability [4, 1]. Of concern is the
possibility of increased adverse effects associated with this
increase in plasma concentration, particularly in people with
cardiovascular compromise or on other medications that may
interact with phenylephrine. Simulation using blood pressure
changes after ophthalmic administration provides an example
of the magnitude of blood pressure change for a typical sub-
ject: a standard 10-mg dose of phenylephrine combined with
paracetamol could result in an increase in MAP of more than
10 mmHg (Fig. 2). We report considerable between-subject
variability that was unexplainable from the limited cohort in-
vestigated. The impact of age, existing hypertension and oph-
thalmic preparation dose accuracy are covariates that require
further investigation.
An important consideration is the substantial variability in
Cmax [4]: a subgroup of the population would be exposed to
relatively higher phenylephrine plasma concentrations than
the population mean data would suggest, leading to more se-
rious adverse events. Indeed, one case report describes
haemorrhagic stroke in an otherwise healthy female taking
phenylephrine and paracetamol in combination for treatment
of cold and flu symptoms [36]. It is also possible that others
without underlying hypertension could also be compromised.
It has been estimated that a 20-mmHg increase in blood pres-
sure would occur with a 45-mg phenylephrine dose in normo-
tensive patients [8], an observation consistent with our current
simulation. It is possible that any given individual may expe-
rience a plasma concentration similar to that seen with a 45-
mg dose when 10 mg phenylephrine is combined with para-
cetamol. Systemic or pulmonary hypertension is also reported
in children (6 months–14 years) administered 10 % ophthal-
mic drops [43].
When medications are administered OTC, the burden of
safety should be high—with only 40 % of consumers reading
the packet label when they take a medicine for the first time
and only 7 % reading safety information and warnings [44],
and changing labelling to reduce the risk of adverse events is
ineffective. In addition, more than one third of consumers take
Fig. 2 The relationship between phenylephrine concentration and MAP
in patients undergoing ophthalmic surgery
Fig. 3 Pharmacodynamic
parameter estimates from patients
(mean age 34.3 years, 70 kg)
undergoing ophthalmic surgery
were combined with derived
pharmacokinetic estimates from
the current study to simulate mean
time-concentration (solid lines)
and mean arterial blood pressure
changes (dashed lines) that might
occur when given oral
phenylephrine with and without
paracetamol
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more than the recommended dose of an OTC medication be-
lieving that it will increase the effectiveness of the medication
and an additional 30 % combine different OTC medicines to
treat different symptoms [44] leading to the potential for over-
dose of any single active ingredient and the associated adverse
effects.
In 2007, the FDA determined that there was insufficient
data to support increasing the dose to the higher 25 mg whilst
maintaining a similar safety profile to the 10-mg dose [45]. At
the same time, the committee concluded that Bcomparisons of
the pharmacokinetics of single-ingredient products versus
multiple ingredient products^ and Bsafety evaluations of the
effects of phenylephr ine on blood pressure and
cardiovasculature and use of phenylephrine in patients with
important comorbidities such as BPH, hypertension or diabe-
tes mellitus^ be conducted [45]. Whilst there are now some
data on the interaction pharmacokinetics of phenylephrine, the
consequences to the population of the OTC co-administration
of phenylephrine and paracetamol remain difficult to define.
The literature reviewed here suggests that this increased phen-
ylephrine exposure could be associated with many, potentially
life-threatening adverse events in individuals both with under-
lying cardiovascular compromise and those who are otherwise
healthy. Despite the FDA’s call for studies almost a decade
ago, there remain no studies specifically examining the safety
profile of phenylephrine in populations with underlying com-
promise, nor are there any studies examining the effects of
chronic use of phenylephrine despite the potential safety
burden.
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